Rock Springs Capital Management LP Graphite Bio, Inc. Transaction History

Rock Springs Capital Management LP

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 15, 2022	SELL	$2.14 - $5.23 $3.83 Million - $9.37 Million	-1,790,754 Closed	0 $0
Q1 2022 May 16, 2022	SELL	$5.1 - $13.06 $1.47 Million - $3.76 Million	-288,156 Reduced 13.86%	1,790,754 $9.13 Million
Q4 2021 Feb 14, 2022	BUY	$8.41 - $16.71 $18,502 - $36,762	2,200 Added 0.11%	2,078,910 $25.8 Million
Q3 2021 Nov 15, 2021	SELL	$15.81 - $28.39 $1.19 Million - $2.13 Million	-75,028 Reduced 3.49%	2,076,710 $34 Million
Q2 2021 Aug 16, 2021	BUY	$18.5 - $30.73 $39.8 Million - $66.1 Million	2,151,738 New	2,151,738 $66.1 Million

637K

Ticker GRPH
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 58,211,200
Description
Graphite Bio, Inc., a clinical-stage gene editing company, engages in developing therapies for serious and life-threatening diseases in the United States. It offers GPH101, a gene-edited autologous hematopoietic stem cell product candidate to directly correct the mutation that causes sickle cell disease and restore normal adult hemoglobin expres...

Get notified when there are updates to the investment portfolio of Rock Springs Capital Management LP, based on Form 13F filings with the SEC.

Stay updated on Rock Springs Capital Management LP with notifications on news.